Healthcare
Vaccine trialled by Moderna and Merck stops skin cancer returning
A new jab extended the length of time patients were cancer free, but it is unclear for how long.
Company
MRK
Merck
No market stories in the last 7 days. The latest coverage is below.
- 7-day mood
- —Not enough data
- Stories, 7 days
- 0
- Last 24 hours
- 0no baseline yet
- Sources
- 16in the latest 30
Mood and coverage · last 7 days
Market chart- Merck · 6-hour average
- Hourly reading
- Stories per hour
No scored stories in the last 7 days.
View as table
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
Latest on Merck
Newest firstHealthcare
Moderna stock surges as melanoma vaccine trial shows "landmark moment"
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
Healthcare
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Healthcare
Stanford is running 37,000 AI agents as a virtual biotech - and one of its drug designs got independently confirmed by Merck
For developers, the operating assumption has been one engineer, one agent - the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate…
Markets
Stocks making the biggest moves premarket: McDonald's, Caterpillar, Palantir, Merck & more
These are the stocks posting the largest moves in early trading.
Healthcare
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
Healthcare
FDA signs off on Merck's cholesterol-lowering pill - the first oral treatment of its kind
The pill, branded as Lipfendra, is intended to treat patients with hypercholesterolemia, including those with hereditary forms of the disease, which causes ele…
Finance
5 Trade Ideas for Monday:American Express, eBay, Merck, Microsoft and Sherwin-Williams
5 Trade Ideas for Monday: American Express, eBay, Merck, Microsoft and Sherwin-Williams Posted by Greg Harmon on July 4th, 2026 5 Trade ideas excerpted from th…
Markets
Stocks making the biggest moves premarket: AeroVironment, Strategy, Merck & more
These are the stocks posting the largest moves premarket.
Healthcare
Germany's Merck to buy Bio-Techne for $11.3 billion
Merck KGaA has agreed to acquire biotech firm Bio-Techne for $11.3 billion, the German science and healthcare firm said in a statement on Thursday.
AI
Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first.
Merck is using AI agents to cut drug discovery cycles by a third and ship compliant marketing materials up to 80% faster - but VP of Digital Platforms Sean Fin…
Markets
Dow Jones Hits Record Highs, DELL Jumps 15%: Stock Market Today
U.S. stocks pushed higher by midday Friday, with the Dow Jones Industrial Average punching to a fresh record high as a powerful AI-led rally in chip and PC nam…
Markets
Stocks making the biggest moves premarket: IMAX, Merck, Estee Lauder & more
These are the stocks posting the largest moves premarket.
Healthcare
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Healthcare
Merck shares are forming a bullish chart pattern, and a breakout could be on the horizon
The pharmaceutical giant is a standout performer within the health-care sector, and the stock could be poised for a big jump.
Healthcare
Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires
Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cance…
Healthcare
Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal
Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia.
Healthcare
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Healthcare
Medical Stocks To Add to Your Watchlist - March 5th
Eli Lilly and Company, Medline, Johnson & Johnson, AbbVie, UnitedHealth Group, Merck & Co., Inc., and McKesson are the seven Medical stocks to watch today, acc…
Healthcare
Merck Mayo AI Partnership Aims To Sharpen Drug Discovery Decisions
Merck (NYSE:MRK) and Mayo Clinic announced a new research and development partnership focused on using artificial intelligence and multimodal clinical data for…
Healthcare
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more
These are the stocks posting the largest moves in early trading.
Healthcare
Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year
Merck's stock falls as the full-year revenue and profit outlooks were below expectations.
Healthcare
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.
Healthcare
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy
Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil.
Healthcare
Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
Healthcare
FDA OKs New Keytruda Shot for Cancer
Merck says an injected version of its blockbuster infusion Keytruda is quicker and easier. But it stands to slow the adoption of cheaper competitors, increasin…
Markets
Dow Movers: WMT, MRK
In early trading on Thursday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.2%. Year to da…
Healthcare
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo Nordisk.
Healthcare
Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.
Markets
Dow Movers: SHW, MRK
In early trading on Tuesday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.6%. Year to dat…